Myron Schwartz, MD
Transplant Surgery · New York, NYNPI 1689640054
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $22,045 of the $27,044 with a category attached, or 81.5%. 11 manufacturers reported payments, led by Merck at 41.3% of the total. Reporting peaked in 2023 at $11,319 and has fallen 99.1% since, to $100 in 2025.
Across 43 payments — averaging $628.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$11K
- Regeneron$4K
- Genentech USA, Inc.$4K
- Astrazeneca UK Limited$3K
- Boston Scientific$2K
- Eisai Inc.$2K
- plus $960 from 5 others
Across 18 payments — averaging $9650.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$172K
- Regeneron$2K
What the payments were for
- Consulting fees$22,04582%
- Travel & lodging$2,2808%
- Food & beverage$2,71910%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 4 | $11,169 |
| Regeneron | 7 | $3,923 |
| Genentech USA, Inc. | 5 | $3,899 |
| Astrazeneca UK Limited | 2 | $3,425 |
| Boston Scientific | 9 | $2,168 |
| Eisai Inc. | 1 | $1,500 |
| Johnson & Johnson | 9 | $548 |
| Genentech, Inc. | 3 | $279 |
| AstraZeneca | 1 | $60 |
| Integra Lifesciences Corporation | 1 | $59 |
| Sirtex Medical Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TECENTRIQ$3,757
- TheraSphere Y90 Glass Microspheres 10 GBq$2,092
- IMFINZI$2,055
- Neuwave$330
How this compares
$27,044 in reported general payments places this provider in the 85th percentile of 72 transplant surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 39 | $58,928 |
| VemlidyTenofovir Alafenamide | 14 | $19,066 |
| Tenofovir Disoproxil Fumarate | 33 | $5,585 |
| Entecavir | 12 | $4,598 |
| Ursodiol | 20 | $578 |
Paid to pharmacies, not to this prescriber.
Other transplant surgery in New York
- Kishore IyerNew York$95K
- Jason HawksworthNew York$91K
- Parissa TabrizianNew York$74K
- Lloyd RatnerNew York$32K
- Hautien LiouNew York$31K
- Karim HalazunNew York$28K
- Ron ShapiroNew York$16K
- Gabriel GondolesiNew York$15K
- Lewis TepermanNew York$13K
- Babak OrandiNew York$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.